Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention

Coronary Artery Disease Clinical Trial

— X-PLORER  

Official title:

Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01442792
• Other study ID #: 15572
• Secondary ID: 2011-001094-58
• Status: Completed
• Phase: Phase 2
• Start date: October 12, 2011
• Est. completion date: March 4, 2013

Study information

• Verified date: June 2022
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Balloon angioplasty (Percutaneous Coronary Intervention (PCI)) is commonly used to treat patients with obstructive coronary artery disease (CAD). Although PCI is highly effective for the management of CAD, it can potentiate an existing prothrombotic state around lesion areas. A certain level of anticoagulation is required to perform planned PCI safely and to minimize the periprocedural risk of thrombosis and its attendant complications, including myocardial ischemia and infarction (heart attack). Many different anti-thrombotic regimens have been investigated and are currently in use. The aim of this study is to explore whether Rivaroxaban, as compared to unfractionated heparin, on the background of standard dual antiplatelet therapy, can effectively suppress thrombosis and related adverse ischemic events, upon balloon inflation and stent expansion, during elective PCI, without increasing bleeding. The treatment assignment will be done in a semi-blinded design, eg, no blinding for randomization either to Rivaroxaban (one of the three arms) or the control (UFH) group. However, all will be blinded for the treatment dose of rivaroxaban (either 10mg or 20 mg).The 10 mg rivaroxaban plus 50 IU UFH arm will not be blinded.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: March 4, 2013
• Est. primary completion date: January 29, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female subject aged 18 years or more with no upper age limit and willing to comply with the protocol

• Symptomatic coronary artery disease due to undergo an elective (non-emergent) Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary vessel(s). Cardiac standard troponin at baseline is within the normal limits

Exclusion Criteria:

• Conditions that may increase the risk of the PCI procedure

• Conditions that may increase the risk of bleeding

• Significant valvular heart disease

• Calculated creatinine clearance =30 mL/min

• Current use of anticoagulant drugs including Vitamin K antagonist (VKA), factor IIa or factor XA inhibitors

• Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs)

• Chronic treatment with aspirin > 100mg

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Coronary Artery Disease

Intervention

Drug:
• UFH
Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
• Rivaroxaban (Xarelto, BAY59-7939)
10 mg single dose Rivaroxaban (per os)
• Rivaroxaban (Xarelto, BAY59-7939)
20 mg single dose Rivaroxaban (per os)
• Rivaroxaban (Xarelto, BAY59-7939) and UFH
10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Bayer	Janssen Research & Development, LLC

Countries where clinical trial is conducted

Belgium,  Netherlands, 

References & Publications (1)

Vranckx P, Leebeek FW, Tijssen JG, Koolen J, Stammen F, Herman JP, de Winter RJ, van T Hof AW, Backx B, Lindeboom W, Kim SY, Kirsch B, van Eickels M, Misselwitz F, Verheugt FW. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervent — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of subjects who require bail-out anticoagulant therapy in the context of an ischemic coronary event		During the index Percutaneous Coronary Intervention procedure
Primary	The percentage of subjects who experience an angiographic flow limiting thrombotic event		During the index Percutaneous Coronary Intervention procedure
Primary	The percentage of subjects who experience thrombus formation on the Percutaneous Coronary Intervention equipment		During the index Percutaneous Coronary Intervention procedure
Primary	The percentage of subjects who experience an Myocardial Infarction due to the Percutaneous Coronary Intervention equipment procedure		During the index Percutaneous Coronary Intervention procedure
Secondary	Bleeding (Thrombolysis in Myocardial Infarction major, minor and Bleeding academic research consortium type 2, 3 and 5)		Up to 30 days post index Percutaneous coronary intervention procedure
Secondary	Composite of clinical ischemic events (all death, non-fatal Myocardial Infarction, non-fatal stroke and target lesion revascularization		Up to 30 days post index Percutaneous coronary intervention procedure
Secondary	Coagulation profile of Rivaroxaban (Activated Partial Thromboplastin Time)		1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)
Secondary	Coagulation profile of Rivaroxaban (Prothrombin time)		1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)
Secondary	Coagulation profile of Rivaroxaban (Thrombin Time)		1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)
Secondary	Coagulation profile of Rivaroxaban (Prothrombin Fragment 1+2)		1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)
Secondary	Coagulation profile of Rivaroxaban (Thrombin Anti-thrombin III Complexes)		1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)
Secondary	Coagulation profile of Rivaroxaban (Anti-Xa Activity)		1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)
Secondary	Coagulation profile of Rivaroxaban (endogenous thrombin potential)		1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)
Secondary	Plasma concentration of Rivaroxaban		The day of percutaneous coronary intervention (PCI) (from 2 to 4 hours before to 6-8 hours after PCI)

External Links

•   Click here to find information about studies related to Bayer Healthcare products conducted in Europe
•   Click here to find results for studies related to Bayer products